Products
Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.
AB-25E9 – inhibition of bone degradation
- Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. Read more about AB-25E9
AB-3A4 – invasive carcinomas
- Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4
AB-16B5 – inhibition of EMT
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5
News
- May 1, 2012 Alethia Biotherapeutics Announces Issuance of a Patent for the Use of Anti-Resorptive Antibodies for Treatment of Severe Bone Loss Alethia Press Release 120501 EN ...
- March 9, 2012 Alethia Biotherapeutics Announces the Filing of a US Provisional Patent Application Covering New Treatment Methods for its EMT Inhibitor AB-16B5 Alethia Press Release 120309 EN...
- November 9, 2011 Alethia Biotherapeutics announces promising in vivo results for its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT Alethia Press Release 111109 EN...
Events
- March 31 - April 4, 2012 Alethia Biotherapeutics to present at the AACR Annual Meeting in Chicago, IL, USA. "The EMT inhibitor AB-16B5 interacts with specific isoforms of secreted clusterin". Mario Filion and Gilles Tremblay will be in attendance....
- March 19- 21, 2012 Alethia Biotherapeutics to be part of the BIO Europe Spring 2012 Annual International Partnering Conference in Amsterdam, The Netherlands. Yves Cornellier and Mario Filion will be in attendance....
- January 10 - 12, 2012 Alethia Biotherapeutics to present at the Biotech Showcase 2012 on Tuesday, January 10 at 3:30 PM at the Parc 55 Wyndham San Francisco – Union Square, San Francisco, USA. Yves Cornellier and Mario Filion will be in attendance....